A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Para
Research payments
$1,642,532
Through program year 2025, $1,642,532 in research payments was reported against A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Para, across 113 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $332,081 | 36 |
| 2024 | Research | $252,083 | 42 |
| 2023 | Research | $510,465 | 32 |
| 2022 | Research | $547,902 | 3 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
7 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Otis Powell Atlanta, GA Named on 45 payments
- Mazyar Rouhani West Palm Beach, FL Named on 12 payments
- Edwin Parrilla Rosario Pembroke Pines, FL Named on 10 payments
- D Goldwater Baltimore, MD Named on 8 payments
- Darin Brimhall Las Vegas, NV Named on 7 payments
- Emilio Gonzalez Miami, FL Named on 6 payments
- Modupe Idowu Houston, TX Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.